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Abstract
Background: Toxoplasma gondii infections are prevalent in humans and animals throughout Libya. Current diagnosis
is based on detection of Toxoplasma-specific IgM and IgG. In this study, we established and optimized a diagnostic
PCR assay for molecular diagnosis of T. gondii in Libya.
Methods: From January to December, 2010, 177 blood and serum samples were collected from suspected patients.
This includes: 140 women who have had spontaneous abortions, 26 HIV-positive patients, nine patients with leukemia
and lymphoma, and two infants with ocular infection. Samples were screened for anti-Toxoplasma IgG and IgM
antibodies before DNA extraction. The surface antigen gene 2 (SAG2) was targeted in a semi-nested PCR to amplify a
999 bp and a 614 bp fragment in the first and the second run respectively.
Results: A total of 54/140 (38.5 %) women who have had spontaneous abortions, 23/26 (88 %) HIV patients, 6/9 (66.6 %)
of the leukaemia and lymphoma patients, and one child with ocular infection were seropositive for anti-Toxoplasma IgG
and/or IgM. Genomic DNA was extracted from 38 selected seropositive samples. The PCR was sensitive enough to detect
DNA concentration of 12 ng/μL. PCR analysis was performed for 38 selected seropositive patients (16 women who have
had spontaneous abortions, 15 positive HIV patients, six leukaemia patients and one child with ocular infection). Our
designed primers were successfully amplified in 22/38 (57.9 %) samples; 5/12 (35.7 %) from serum and 17/26 (65.8 %)
from whole blood samples. All PCR positive samples were IgG-positive except two samples which were IgM and IgG &
IgM-positive serum samples respectively. The semi-nested PCR confirmed five more samples. These included two
leukaemia and two HIV-positive whole blood samples and one serum sample from an aborted woman.
Conclusion: The ability of PCR to diagnose active toxoplasmosis is needed in immunocompromised patients and
congenital toxoplasmosis cases, especially when serological techniques fail. For the first time in Libya, we established
and optimized semi-nested PCR of SAG2 gene. The developed PCR method was able to detect as little as 12 ng/μL of
T. gondii DNA and was useful to diagnose the diseases in women who have had spontaneous abortions, HIV-positive
patients, patients with leukemia and lymphoma, and infants with ocular infection.
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Background
Toxoplasma gondii infections are prevalent in humans
and animals worldwide. It has been estimated that one-
third of the world population has been exposed to this
parasite [1, 2]. The infection is acquired by ingesting tissue
cysts from undercooked or raw meat, consuming food or
drink contaminated with oocysts shed by felids, or by acci-
dentally ingesting oocysts from the environment [3].
Although the course of the primary infection is usually
subclinical and the vast majority of infected human popu-
lations remain asymptomatic, the infection can cause
significant morbidity and mortality in certain groups. This
includes encephalitis, chorioretinitis, congenital infection
and neonatal mortality [4]. Transmission to the fetus
occurs in women who acquire their primary infection dur-
ing gestation and can result in visual and hearing loss, men-
tal and psychomotor retardation, seizures, hematological
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abnormalities, hepatosplenomegaly, or death [5]. The glo-
bal annual incidence of congenital toxoplasmosis was esti-
mated to be 190,100 cases [6]. High burdens of congenital
toxoplasmosis, which where estimated as the highest
among all food-borne pathogens [7], were seen in South
America and in some Middle Eastern and low-income
countries [6]. Moreover, toxoplasmic encephalitis due to
reactivation of latent tissue cysts is the most common
clinical presentation of toxoplasmosis among persons with
AIDS [8–11]. The infection is typically observed in the
later stages of human immunodeficiency virus (HIV)
infection, when persons become severely immunosup-
pressed [12, 13]. The incidence of encephalitis in AIDS
patients in the general population is directly related to the
prevalence of anti-T. gondii antibodies [8]. Global sero-
prevalence of toxoplasmosis is continuingly evolving,
subject to regional socioeconomic parameters and popula-
tion habits. It presents in every country in the world and
seropositivity rates range from less than 10 % to over 90 %
[14].
In African countries, numerous studies performed in
the early 1990s with limited follow-up exists even for the
general population of these countries. Recent review by
Pappas et al. [14] summarized prevalence rates in Egypt
(57.9 %), Tunisia (58.4 %), Morocco (50.6 %), Nigeria
(20.8 %), Mali (21 %), Benin (3.6 %), Gabon (71.2 %),
Madagascar (83.5 %), and Senegal (40.2 %). However,
limited studies about Libyan toxoplasmosis are available.
Seroprevalence of toxoplasmosis among Libyan pregnant
women in Benghazi ranges between (44.8 %) [15], (47.4 %)
[16], and (50 %) [17], and among non-pregnant Libyan
women in Tripoli was estimated to be around (18.14 %)
[18], (43.4 %) among adult males, and (43.7 %) of school
children [19]. Gashout et al. has shown that (17.6 %) of
women who suffered from spontaneous abortion in
Tripoli were seropositive for toxoplasmosis [20]. More-
over, prevalence of congenital toxoplasmosis was found to
be (44 %) in Tripoli [21]. However, no comprehensive
epidemiological analysis was done at the national level in
Libya. All previous studies were based on detection of
Toxoplasma-specific IgM and IgG. Specific and sensitive
molecular diagnostic tools have not yet been implemented
and information about disease distribution, parasite life
cycle, and combining risk factors is limited.
Due to their high sensitivity and specificity, molecular
methods are now recognized as an essential diagnostic
tool for maternal and congenital toxoplasmosis [22–30],
toxoplasmosis in immunocompromised individuals [31,
32], and ocular toxoplasmosis [33–35]. In most develop-
ing countries, including Libya, these methods are not
widely used in clinical settings for routine diagnosis and
therapeutic management, as they are expensive and time
consuming techniques. Current diagnosis of toxoplas-
mosis in Libya is based on serological methods which
have varied sensitivity and specificity depending on the
test used [36, 37]. Moreover, serological tests may fail to
detect T. gondii infection in certain immunocomprom-
ised patients due to the fact that the titres of specific
anti-Toxoplasma antibodies may fail to rise at the time
of diagnosis [38–40]. Hence direct observation of the
parasite in biological samples by Polymerase Chain Reac-
tion (PCR) is a major breakthrough for the diagnosis and
management of toxoplasmosis [41].
In this study, we described establishment, optimization,
and application of diagnostic PCR assay to amplify SAG2
gene of T. gondii from Libyan HIV patients, women who
have had spontaneous abortions, leukaemia, and ocular
infection patients who were sero-positive for specific
Toxoplasma antibodies. To the best of our knowledge, this
is the first molecular study of human toxoplasmosis in
Libya focusing on establishment of molecular diagnostic
technique.
Methods
Patients and samples
A total of 177 blood and serum samples were collected
from clinically diagnosed patients during January-
December 2010. This includes; 140 women who have
had spontaneous abortions from out-patient depart-
ments, 26 HIV-positive patients from infectious depart-
ment in Tripoli Central Hospital, nine patients from
African Oncology Institute in Sabrata diagnosed with
leukemia and lymphoma, and two infants with ocular
infection from private Alsharkh Laboratories in Zawia
City. Patient’s data including, age, sex and location,
were collected for epidemiological analysis.
Serologic tests
Approximately 5 ml of venous blood were collected from
each patient. Two ml were added to plain tube to get
serum. The rest was transferred into tube with EDTA for
DNA extraction. Serum was separated from the whole
blood by centrifugation at 3000 rpm for 5 min and
screened for anti-Toxoplasma IgG and IgM antibodies by
using standard ELISA commercial kits (Human Gesell-
schaft für Biochemica und Diagnostica GmbH, Wies-
baden, Germany) in accordance with the manufacturer’s
instruction. Moreover, the Architect Toxo IgG and Toxo
IgM assays (Abbott Laboratories, Wiesbaden, Germany)
was used to confirm ELISA results for a subset of patients
to avoid false negatives.
Parasites preparation and genomic DNA extraction
Reference strain RH (type I) was used as positive control. A
stock solution of 1000 tachyzoites/100 μl of PBS was pre-
pared and kept at − 80 °C until used. The genomic DNA
was extracted from the RH T. gondii tachyzoites, blood
samples spiked with different concentrations of tachyzoites,
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and from patient’s serum and whole blood samples using
PureLink™ Genomic DNA Kit for purification of genomic
DNA (Invitrogen) following the manufacturer’s instruc-
tions. Briefly, cells were lysed and digested with 20 μl of
Proteinase K, RNase A (50 Mm Tris-HCl, Ph 8.0,10 Mm
EDTA) and 200 μl of Lysis/Binding Buffer at 55 °C for
10 min. Absolute ethanol (200 μl) was added and the
mixture was transferred to the PureLink™ Spin column in a
2 ml collection tube and centrifuged for 1 min. The col-
umns were washed twice, and the DNA was eluted from
the columns with 50 μl of elution buffer (10 mM Tris-HCl,
pH 9.0, 0.1 mM EDTA). Spectrophotometric analysis was
applied to measure DNA concentration and purity.
Polymerase chain reactions (PCR) and semi-nested PCR
The surface antigen gene 2 (SAG2), which encode the
tachyzoite surface proteins p22 was targeted as described
elsewhere [42–45] with modifications. Briefly, a fragment
of SAG2 gene (Gene bank: AF 24969) [46] was amplified
using two primers; forward (TOXO 29) and reverse
(TOXO 1027) to produce a 999 bp fragment (Table 1).
Semi-nested PCR was then performed to confirm specifi-
city of first round products by using forward (TOXO 409)
and reverse (TOXO 1027) to produce a 614 bp fragment
(Table 1). We designed all primers by using online Pri-
mer3 Output; http://primer3.ut.ee/.
Conventional PCR was optimized in a 50 μL reaction that
includes; 5 μL of High Fidelity 10× PCR buffer (20 mM
Tris-HCl, pH 7.5, 100 mM KCl, 1 mM Dithiothreitol
(DTT), 0.1 mM EDTA, 0.5 % Tween 20, 0.5 % Nonidet
P40, 50 % glycerol), 4 μL of (25 mM) MgCl2, 5 μL of
(10 mM) dNTPs, 0.5 μL of each (50 pmol) primer, 0.25 μL
of (5U/μl) High Fidelity enzyme mix and 10 μL of DNA
template, and 29.25 μL of ultrapure water. The mixture was
briefly spun and placed in thermal cycler (GenAmp® PCR
system, Applied Biosystem). The reaction conditions were
optimized using number of modifications; temperature for
primer annealing (58–60 °C), MgCl2 concentration (1.5, 2,
3, 4 mM), enzyme mix (1.1, 1.25 and 2.75U/μl) and primer
concentration (12.5 16.5, 25, 41, and 45 μM).
PCR sensitivity was assessed by using serial dilutions
of T. gondii DNA (RH strain) ranging from 12.5, 25, 50
and 100 ng/μl input per 50 μl PCR reaction as described
previously [45]. The dilutions were tested by PCR to de-
termine the minimum DNA concentration per reaction
that could be detected by this protocol. Moreover, PCR
sensitivity was tested by mixing 200 μl of whole blood
with different concentrations of T. gondii tachyzoites of
the RH strain (10, 100 and 1000 parasites) prior to ex-
traction according to Howe et al. [44].
For semi-nested PCR, we took 5 μL of a 1:10 diluted
PCR amplicon from the first-round as a template. The
protocol for reaction conditions was used as described
for first round PCR amplification. Each amplification
assay contained a negative control (negative sample for
IgG and IgM T. gondii antibodies and/or ultrapure
water) and one positive control (2 μL DNA from RH T.
gondii tachyzoites). To guarantee the reliability of the re-
sults and detect any possible contamination, all samples
were processed in duplicate. The test result was consid-
ered positive if the amplified DNA fragment was clearly
visible in both samples.
For DNA detection, 5 μL of amplicons were analyzed on
1.7 % agarose gel by electrophoresis and visualized by UV
light and then photographed under an ultraviolet translu-
minator. 100 bp plus DNA Ladder (Bioron) was used as a
marker. Gel quantification analysis of the bands amplified
from blood samples spiked with different concentrations
Table 1 Design of SAG2 PCR and semi-nested PCR analysis
AnT Annealing temperature
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of tachyzoites was carried out using ImageJ 1.46r software
(National Institutes of Health, Bethesda, MA, USA).
Ethical considerations
All aspects of the study were revised and approved by the
ethics committee of the Libyan National Centre for Disease
and Control. Confidentiality was ensured through secure
data management and no personal identifiers were in the
computer system. Data and samples were labeled with an-
onymous identification numbers. Informed written consent
was obtained from all participants. Since two study partici-
pants were infants, parents/guardians provided consent on
their behalf. Test results were confidentially disclosed to
the subjects following post-test counseling.
Results
ELISA results for T. gondii IgM and IgG antibodies
One hundred and forty women who have had spontaneous
abortions, median age 27 year (range19–41 year) in the first
16 weeks of gestation, were clinically diagnosed and tested
for Toxoplasma infection with ELISA. The mean length of
pregnancy was 10 weeks (range 1–16 weeks) at the time of
abortion and sample collection.
A total of 54/140 (38.5 %) women who have had spon-
taneous abortions were seropositive; 36 (66.6 %) were
positive for IgG antibodies, 12 (22.2 %) for IgG and IgM
antibodies, and 6 (11.1 %) for IgM. Moreover, 4 of the
IgG-positive women had a history of repeated abortion.
Twenty six HIV positive patients (14 male and 12 female,
mean age 37 years old) were tested for T.gondii infection.
The HIV-positive patients were considered seropositive if
the ELISA result of serum samples had detectable specific
Toxoplasma IgG antibodies with titer ≥ 10 IU/ml. A total of
23/26 (88 %) patients were IgG positive among which 17
(74 %) had a CD4 cell-count less than 100 cells/μl of blood.
CD4 levels in HIV-positive patients with seropositive toxo-
plasmosis (range, 3 to 273 CD4 cells/μl of blood) were
lower than seronegative patients (range, 345 to 463 CD4
cells/μl of blood).
However, 6/9 (66.6 %) of the leukaemia and lymphoma
patients (five males and four females, mean age 36 year),
and one child (male, 4 months) with ocular infection
were IgG positive (Table 2). All samples retested with
Architect Toxo IgG and Toxo IgM assays confirmed the
ELISA results without any discrepancies.
Genomic DNA Extraction and PCR optimization
Genomic DNA was extracted from 38 selected seropositive
and clinically diagnosed toxoplasmosis patients. The DNA
concentration ranged from 16 to 350 ng/μl. Optimum PCR
cycling parameters were: 94 °C for 4 min, then 35 cycles at
94 °C for 1 min, 58 °C for 1 min and 72 °C for 2 min. The
PCR was completed with 7 min at 72 °C. Under these
conditions, the PCR was sensitive enough to detect DNA
concentration of 12 ng/μL of extracted DNA from purified
parasite (Fig. 1a). Analytic sensitivity of 10, 100, and 1000
tachyzoites in 200 μl whole blood was predicted. We did
the PCR for each concentration in triplicate and run a gel
for all PCR products together, then we repeated the PCR
once again to obtain a gel photo (Fig. 1b). Wile no product
was detected from whole blood sample where no parasites
were added (Fig. 1b).
PCR amplification of SAG2 locus
PCR analysis was performed for 38 selected patients (16
women who have had spontaneous abortions, 15 positive
HIV patients, six leukaemia patients, and one child with
ocular infection). All selected cases were strong sero-
positive; these included 33 samples that were positive only
for IgG antibodies, four samples that were positive for
both IgM and IgG antibodies, and one sample were posi-
tive for IgM.
Amplification of the SAG2 gene with our designed
primers was successful in 22/38 (57.9 %) samples; 5/12
(35.7 %) from serum and 17/26 (65.8 %) from whole blood
samples. All PCR positive samples was IgG-positive except
two samples; one IgM-positive and one IgG and IgM-
positive serum samples from women who have had spon-
taneous abortions. Table 2 summarizes serological and
corresponding PCR results.
Figure 2a shows the PCR products resulted from the first
round PCR and the semi-nested PCR which were 999 bp
and 619 bp, respectively. Semi-nested PCR was done for
PCR products which gave faint bands in the first round. By
this PCR we confirmed five more samples. These included
two leukaemia and two positive HIV whole blood samples,
and one aborted woman serum sample (Fig. 2b).
Table 2 Serological and corresponding PCR results
Groups Serology Results PCR and semi-nested PCR Results
No. of Samples IgG IgG&IgM IgM No. of Samples Serum Whole Blood
Women who have had spontaneous abortions 140 36 12 6 16 2/6 6/10
HIV 26 23 - - 15 3/6 6/9
Leukaemia and lymphoma patients 9 6 - - 6 - 4/6
Ocular infection 2 1 - - 1 - 1/1
Total 177 66 12 6 38 5/12 17/26
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Discussion
PCR has been consistently used to detect DNA of T.
gondii in various biological samples and has showed
higher sensitivity in diagnosis compared to serological
tests and culture [25, 47–50]. Moreover, the potential of
PCR to diagnose active toxoplasmosis is of great import-
ance for immunocompromised patients and congenital
toxoplasmosis particularly when serological techniques
failed [51]. Most researchers have used the B1 and SAG1
for detection of Toxoplasma [43, 52–54]. However, a
nested PCR assay based on the polymorphic SAG2 locus
was developed [43, 44]. SAG2 gene encodes two separate
forms of the surface tachyzoite protein p22 that are
recognized by strain-specific monoclonal antibodies and
allow for adequate genotyping of T. gondii [44, 55]. The
genetic analysis based on this gene requires a small
amount of DNA, thus allowing it to be amplified directly
from clinical samples [44].
For the very first time in Libya, we developed a sensitive
and specific PCR of SAG2 gene to detect T. gondii in clin-
ical samples. Positive results were detectable after the first
round of PCR. However, semi-nested PCR was essential to
confirm specificity of first round products with faint band
intensity. This investigation was based on the combined
results of positive serological tests for IgG and/or IgM
antibodies, which confirms T. gondii DNA in whole blood
and serum samples among different patients (women with
history of repeated abortion, positive HIV patients, leukae-
mia and congenital cases).
As for all parasitic diseases, the PCR diagnosis of
toxoplasmosis is not standardized [41]. Therefore, we
adjusted PCR conditions to give optimum sensitivity
and specificity without appearance of artifacts. The
use of this assay allowed for a highly sensitive detec-
tion of less than 10 tachyzoites of T. gondii DNA and
a minimum concentration of 12 ng/ml. The detection
limit of the conventional PCR varied depending on
the amounts of pure T. gondii tachyzoites that were
mixed with whole blood. A decreased performance of
conventional PCR may be expected when exceeding
certain amount of non-specific DNA in a reaction
volume. Interestingly, the conventional single step
PCR assay targeting SAG2 in the first round was suc-
cessful as in the previous studies used a nested PCR
Fig. 1 a: PCR amplification performed with various DNA concentrations. The quantity of DNA is shown above each lane, minimum amount detected
was 12 ng. ve + =positive control. b: PCR for detection of T. gondii DNA in whole blood samples spiked with 101, 102 and 103 tachyzoites. Lane N=whole
blood without tachyzoites, +ve = positive control (DNA extracted from pure tachyzoites). The bands were quantified by using the software ImageJ. The
percentage of the area under the curve was 101 = 12 %, 102 = 25 %, 103 = 30 % and+ ve =33 %. -ve = negative control, M= 100-bp DNA ladder (BIORON)
1000 bp
619 bp
999 bp
500 bp
a
b
Fig. 2 a: PCR amplification of T. gondii SAG2 gene in 1.7 % agarose gel. Lane 1 and 2 = positive HIV whole blood samples. Lanes 3 and 4 = leukaemia
whole blood samples. Lane 5 and 6 = aborted woman serum and whole blood respectively. Lane 7 = patient with ocular infection. Ve + = positive control
(RH strain). b: Semi-nested PCR amplification of T. gondii SAG2 gene for samples with faint band in the first PCR run. Lanes; 1 and 2 = positive HIV whole
blood samples. Lanes 3 and 5 = leukaemia whole blood samples. Lane 4; aborted woman serum sample. Lane 6 = seronegative toxoplasmosis aborted
woman whole blood sample. Lane P= positive control (RH strain). Ve- = is negative control (blanked water), M= 100 bp DNA Ladder (BIORON)
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protocol targeting the same gene [44, 55]. Moreover,
the semi-nested PCR system may increase the sensi-
tivity due to its dilution effect between the first and
the second round of PCR if inhibitory factors are
present. However, the risk of carry-over contamin-
ation between first and second rounds of PCR should
be considered to avoid false positive results which
may make this approach less suitable in the routine
laboratory tests.
In the present study, discrepancies between serology
and PCR results were detected since 22/38 (57.9 %)
of tested seropositive samples were PCR positive. Pos-
sible explanation is that the clearance time for Toxo-
plasma DNA from the patient’s blood was estimated
to be 5.5–13 weeks [56]. Based on this, the presence
of Toxoplasma DNA in the peripheral blood probably
indicates a recent infection or apparent parasitaemia
that is likely to be clinically significant. Conversely, a
small number of parasites might have been released
from tissue into the blood at a subclinical level and
their presence can be detected only by PCR [57].
In this study, T. gondii DNA was detected only in 2/5
IgM positive women who have had spontaneous abor-
tions and 3/11 women showed no evidence of infection
by PCR, though IgG antibodies were detected. This can
be attributed to the presence of a long standing im-
munity to toxoplasmosis or cross-reactive antibodies
[58, 59] and confirm the sensitivity and specificity of
PCR analysis for detecting recent infection in early
pregnancy [60]. This is in agreement with previous
reports that PCR is recommended over serologic tech-
niques for diagnosis of toxoplasmosis [61–63].
Toxoplasma DNA was detected in one of two children
clinically diagnosed with ocular infection. The first child
was both PCR and seropositive at 4 months of age. The
second child was both PCR and seronegative at 8 years
of age. This indicated that our PCR assay may be used
to confirm ocular toxoplasmosis and to differentiate it
from other ocular diseases. Our results are in agreement
with previously published reports [64].
The emergence of human immunodeficiency virus
HIV in Libya has increased the need for more sensitive
and reliable diagnostic methods to diagnose opportun-
istic infections like toxoplasmosis. Latent T. gondii
infection in 30–50 % of HIV patients have a high risk
of progressing to toxoplasmic encephalitis [65, 66]. In
our study, the T.gondii DNA was detected in (60 %) of
the seropositive toxoplasmosis HIV/AIDS patients with
CD4 count less than 100 cells/μl. Moreover, the average
CD8 count was significantly higher for patients who
had negative PCR result (data not shown). Serological
tests are limited with delayed or impaired production
of antibodies in immunocompromised patients. Hence,
PCR approaches are superior for diagnosing such cases.
Conclusion
Diagnosis of T. gondii infection in Libya is based on sero-
logical detection of specific anti- Toxoplasma immuno-
globulin, which has varied sensitivity and specificity, may
fail to detect infection especially in immunocompromised
patients. For the first time in Libya, we established and
optimized semi-nested PCR of SAG2 gene, which is a reli-
able diagnostic technique with adequate sensitivity and
specificity when used to detect T. gondii DNA in different
clinical settings. The developed PCR method was able to
detect as little as 12 ng/μL of T. gondii DNA and was
useful to diagnose the disease in women who have had
spontaneous abortions, HIV-positive patients, patients
with leukemia and lymphoma, and infants with ocular
infection.
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